BTK Resistance Mutation, China CAR-T Review, and BET Inhibitor Insights Mark Cancer Research Advances

Researchers have identified a rare mutation, BTK A428D, that enables blood cancers to evade both approved BTK inhibitors and next-generation BTK degraders, according to a study published in Cancer Discovery. In parallel, China is poised to deliver the world's first approved CAR-T therapy for gastric cancer, and a Max Planck Institute study has uncovered why BET inhibitors have often failed in clinical trials.

The study, 'Molecular and Structural Basis of Pan-Resistance to BTK Degraders and Inhibitors,' was led by scientists at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine and collaborators. BTK inhibitors have transformed treatment for chronic lymphocytic leukemia (CLL) and other B-cell malignancies by blocking a protein that cancer cells depend on for growth and survival. BTK degraders, a newer class of drugs, were designed to eliminate the BTK protein altogether and overcome resistance to earlier therapies. Previous studies showed that common resistance mutations remained susceptible to BTK degraders, but the newly identified A428D mutation appears to evade both approaches. Molecular, biochemical, and structural analyses found that the mutation dramatically alters the shape of the BTK protein, preventing drugs from attaching to their target. The mutation also reduces the fitness of cancer cells, which may explain why it is seen primarily in patients treated with BTK degraders rather than in those receiving BTK inhibitors alone. Patients who develop these resistance mutations do not have any options for further BTK-targeted therapy. In preclinical models, combining BTK degraders with drugs targeting the BCL2 protein prevented resistant cancer cells from emerging, supporting further investigation of combination therapy for CLL.

In solid-tumor CAR-T innovation, China is poised to deliver the world's first approved CAR-T therapy for gastric cancer. CARsgen Therapeutics' satricabtagene autoleucel (satri-cel, CT041), which targets Claudin 18.2 for advanced gastric and gastroesophageal cancers, is under review by the National Medical Products Administration (NMPA) and is expected to become available in China in the first half of 2026. The anticipated approval signals a shift in oncology treatment, expanding CAR-T beyond hematological malignancies and intensifying competition in the solid tumor landscape.

A separate study from the Max Planck Institute of Immunobiology and Epigenetics in Freiburg helps explain why BET inhibitors have often underperformed in clinical trials. Despite solid preclinical science, patient outcomes showed modest benefits, notable side effects, and no reliable way to predict responders. The team found that two major BET proteins, BRD2 and BRD4, carry out different tasks at separate stages of gene activation. BRD4 controls a later step by releasing RNA Polymerase II, while BRD2 works earlier, helping assemble and organize the molecular components needed to begin transcription. BRD2 depends on histone acetylations added by the enzyme MOF and organizes the transcription machinery by forming clusters at gene sites; removing the clustering region slowed transcription almost as much as removing the entire protein. The findings suggest that future therapies may focus on the distinct roles of BRD2 and BRD4 rather than broadly blocking the shared chromatin-binding function of BET proteins. The study was published in Nature Genetics.

In acute myeloid leukemia (AML), a Worldwide Cancer Research-funded project at the University of Cambridge is investigating the DNMT3A-R882 mutation, which appears to drive the disease and make it grow quickly. AML is an aggressive blood cancer that can be difficult to treat, with over 2,900 people in the UK diagnosed every year and particularly poor survival rates. The team will map how the mutation alters gene activity through interactions with key molecules and will test potential targets and therapies, including some existing drugs that may reverse the mutation's actions. The project, supported by an award of £239,952, aims to find new ways to treat, prevent, or delay AML.